ABSTRACT
Mitochondrial DNA (mtDNA) depletion syndrome (MDS; MIM 251880) is a prevalent cause of oxidative phosphorylation disorders characterized by a reduction in mtDNA copy number. The hitherto recognized disease mechanisms alter either mtDNA replication (POLG (ref. 1)) or the salvage pathway of mitochondrial deoxyribonucleosides 5'-triphosphates (dNTPs) for mtDNA synthesis (DGUOK (ref. 2), TK2 (ref. 3) and SUCLA2 (ref. 4)). A last gene, MPV17 (ref. 5), has no known function. Yet the majority of cases remain unexplained. Studying seven cases of profound mtDNA depletion (1-2% residual mtDNA in muscle) in four unrelated families, we have found nonsense, missense and splice-site mutations and in-frame deletions of the RRM2B gene, encoding the cytosolic p53-inducible ribonucleotide reductase small subunit. Accordingly, severe mtDNA depletion was found in various tissues of the Rrm2b-/- mouse. The mtDNA depletion triggered by p53R2 alterations in both human and mouse implies that p53R2 has a crucial role in dNTP supply for mtDNA synthesis.
Subject(s)
Cell Cycle Proteins/genetics , DNA, Mitochondrial/genetics , Gene Deletion , Mitochondrial Diseases/etiology , Mutation/genetics , Ribonucleotide Reductases/genetics , Tumor Suppressor Protein p53/metabolism , Animals , Cell Cycle Proteins/physiology , Cells, Cultured , DNA Mutational Analysis , Female , Fibroblasts , Homozygote , Humans , Infant, Newborn , Lod Score , Male , Mice , Mice, Knockout , Mitochondria, Muscle , Mitochondrial Diseases/pathology , Molecular Sequence Data , Pedigree , Ribonucleotide Reductases/physiology , Tumor Suppressor Protein p53/geneticsABSTRACT
Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a non-coding CTG repeat expansion that, in particular, provokes functional alteration of CUG-binding proteins. As a consequence, several genes with misregulated alternative splicing have been linked to clinical symptoms. In our search for additional molecular mechanisms that would trigger functional defects in DM1, we took advantage of mutant gene-carrying human embryonic stem cell lines to identify differentially expressed genes. Among the different genes found to be misregulated by DM1 mutation, one strongly downregulated gene encodes a transcription factor, ZNF37A. In this paper, we show that this defect in expression, which derives from a loss of RNA stability, is controlled by the RNA-binding protein, CUGBP1, and is associated with impaired myogenesis-a functional defect reminiscent of that observed in DM1. Loss of the ZNF37A protein results in changes in the expression of the subunit α1 of the receptor for the interleukin 13. This suggests that the pathological molecular mechanisms linking ZNF37A and myogenesis may involve the signaling pathway that is known to promote myoblast recruitment during development and regeneration.
Subject(s)
Alternative Splicing/genetics , Kruppel-Like Transcription Factors/genetics , Muscle Development/genetics , Myotonic Dystrophy/genetics , Trinucleotide Repeat Expansion/genetics , Cell Line , Cell Nucleus/genetics , Cell Nucleus/metabolism , Embryonic Stem Cells , Humans , Interleukin-13 Receptor alpha1 Subunit/genetics , Interleukin-13 Receptor alpha1 Subunit/metabolism , Mutation , Myotonic Dystrophy/physiopathology , Signal Transduction/geneticsABSTRACT
Patients with myotonic dystrophy type 1 exhibit a diversity of symptoms that affect many different organs. Among these are cognitive dysfunctions, the origin of which has remained elusive, partly because of the difficulty in accessing neural cells. Here, we have taken advantage of pluripotent stem cell lines derived from embryos identified during a pre-implantation genetic diagnosis for mutant-gene carriers, to produce early neuronal cells. Functional characterization of these cells revealed reduced proliferative capacity and increased autophagy linked to mTOR signaling pathway alterations. Interestingly, loss of function of MBNL1, an RNA-binding protein whose function is defective in DM1 patients, resulted in alteration of mTOR signaling, whereas gain-of-function experiments rescued the phenotype. Collectively, these results provide a mechanism by which DM1 mutation might affect a major signaling pathway and highlight the pertinence of using pluripotent stem cells to study neuronal defects.
Subject(s)
Embryonic Stem Cells/cytology , Myotonic Dystrophy/metabolism , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , TOR Serine-Threonine Kinases/metabolism , Apoptosis/genetics , Apoptosis/physiology , Blotting, Western , Cell Line , Cell Proliferation , Cellular Senescence/genetics , Cellular Senescence/physiology , Electrophoresis, Polyacrylamide Gel , Humans , Immunohistochemistry , In Situ Hybridization , Myotonic Dystrophy/genetics , Real-Time Polymerase Chain Reaction , TOR Serine-Threonine Kinases/geneticsABSTRACT
Huntington's disease (HD) is characterized by a late clinical onset despite ubiquitous expression of the mutant gene at all developmental stages. How mutant huntingtin impacts on signalling pathways in the pre-symptomatic period has remained essentially unexplored in humans due to a lack of appropriate models. Using multiple human embryonic stem cell lines derived from blastocysts diagnosed as carrying the mutant huntingtin gene by pre-implantation genetic diagnosis, we explored early developmental changes in gene expression using differential transcriptomics, combined with gain and loss of function strategies. We demonstrated a down-regulation of the HTT gene itself in HD neural cells and identified three genes, the expression of which differs significantly in HD cells when compared with wild-type controls, namely CHCHD2, TRIM4 and PKIB. Similar dysregulation had been observed previously for CHCDH2 and TRIM4 in blood cells from patients. CHCHD2 is involved in mitochondrial function and PKIB in protein kinase A-dependent pathway regulation, which suggests that these functions may be precociously impacted in HD.
Subject(s)
Embryonic Stem Cells/metabolism , Huntington Disease/genetics , Mutation/genetics , Neurons/metabolism , Transcription, Genetic , Transcriptome/genetics , Cell Line , Embryonic Stem Cells/pathology , Gene Expression Profiling , Gene Expression Regulation , Humans , Huntingtin Protein , Models, Biological , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neural Stem Cells/metabolism , Neural Stem Cells/pathology , Neurons/pathology , Reproducibility of Results , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Mesenchymal stem cells (MSCs) are present in a wide variety of tissues during development of the human embryo starting as early as the first trimester. Gene expression profiling of these cells has focused primarily on the molecular signs characterizing their potential heterogeneity and their differentiation potential. In contrast, molecular mechanisms participating in the emergence of MSC identity in embryo are still poorly understood. In this study, human embryonic stem cells (hESs) were differentiated toward MSCs (ES-MSCs) to compare the genetic patterns between pluripotent hESs and multipotent MSCs by a large genomewide expression profiling of mRNAs and microRNAs (miRNAs). After whole genome differential transcriptomic analysis, a stringent protocol was used to search for genes differentially expressed between hESs and ES-MSCs, followed by several validation steps to identify the genes most specifically linked to the MSC phenotype. A network was obtained that encompassed 74 genes in 13 interconnected transcriptional systems that are likely to contribute to MSC identity. Pairs of negatively correlated miRNAs and mRNAs, which suggest miRNA-target relationships, were then extracted and validation was sought with the use of Pre-miRs. We report here that underexpression of miR-148a and miR-20b in ES-MSCs, compared with ESs, allows an increase in expression of the EPAS1 (Endothelial PAS domain 1) transcription factor that results in the expression of markers of the MSC phenotype specification.
Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , Gene Expression Profiling , Mesenchymal Stem Cells/metabolism , MicroRNAs/genetics , RNA, Messenger/genetics , Base Sequence , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Differentiation/genetics , Cell Line , Embryonic Stem Cells/cytology , Embryonic Stem Cells/metabolism , Gene Regulatory Networks/genetics , Humans , Mesenchymal Stem Cells/cytology , MicroRNAs/metabolism , Molecular Sequence Data , Phenotype , RNA, Messenger/metabolism , Transcription, Genetic , Up-Regulation/geneticsABSTRACT
Mutations of the huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD). HTT modulates mitotic spindle orientation and cell fate in mouse cortical progenitors from the ventricular zone. Using human embryonic stem cells (hESC) characterized as carrying mutations associated with adult-onset disease during pre-implantation genetic diagnosis, we investigated the influence of human HTT and of an adult-onset HD mutation on mitotic spindle orientation in human neural stem cells (NSCs) derived from hESCs. The RNAi-mediated silencing of both HTT alleles in neural stem cells derived from hESCs disrupted spindle orientation and led to the mislocalization of dynein, the p150Glued subunit of dynactin and the large nuclear mitotic apparatus (NuMA) protein. We also investigated the effect of the adult-onset HD mutation on the role of HTT during spindle orientation in NSCs derived from HD-hESCs. By combining SNP-targeting allele-specific silencing and gain-of-function approaches, we showed that a 46-glutamine expansion in human HTT was sufficient for a dominant-negative effect on spindle orientation and changes in the distribution within the spindle pole and the cell cortex of dynein, p150Glued and NuMA in neural cells. Thus, neural derivatives of disease-specific human pluripotent stem cells constitute a relevant biological resource for exploring the impact of adult-onset HD mutations of the HTT gene on the division of neural progenitors, with potential applications in HD drug discovery targeting HTT-dynein-p150Glued complex interactions.
Subject(s)
Mutation , Nerve Tissue Proteins/genetics , Neural Stem Cells/metabolism , Adult , Age of Onset , Alleles , Antigens, Nuclear/analysis , Cell Cycle Proteins , Cells, Cultured , Dynactin Complex , Dyneins/analysis , Genes, Dominant , Human Embryonic Stem Cells/cytology , Humans , Huntingtin Protein , Microtubule-Associated Proteins/analysis , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/physiology , Neural Stem Cells/ultrastructure , Nuclear Matrix-Associated Proteins/analysis , Peptides/analysis , Pluripotent Stem Cells/cytology , Polymorphism, Single Nucleotide , Protein Transport , RNA Interference , RNA, Small Interfering/genetics , Spindle Apparatus/ultrastructure , Subcellular Fractions/chemistry , Trinucleotide Repeat ExpansionABSTRACT
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from polyglutamine expansion in the huntingtin (HTT) protein and for which there is no cure. Although suppression of both wild type and mutant HTT expression by RNA interference is a promising therapeutic strategy, a selective silencing of mutant HTT represents the safest approach preserving WT HTT expression and functions. We developed small hairpin RNAs (shRNAs) targeting single nucleotide polymorphisms (SNP) present in the HTT gene to selectively target the disease HTT isoform. Most of these shRNAs silenced, efficiently and selectively, mutant HTT in vitro. Lentiviral-mediated infection with the shRNAs led to selective degradation of mutant HTT mRNA and prevented the apparition of neuropathology in HD rat's striatum expressing mutant HTT containing the various SNPs. In transgenic BACHD mice, the mutant HTT allele was also silenced by this approach, further demonstrating the potential for allele-specific silencing. Finally, the allele-specific silencing of mutant HTT in human embryonic stem cells was accompanied by functional recovery of the vesicular transport of BDNF along microtubules. These findings provide evidence of the therapeutic potential of allele-specific RNA interference for HD.
Subject(s)
Brain/cytology , Genetic Therapy/methods , Huntington Disease/therapy , Mutant Proteins/antagonists & inhibitors , Nerve Tissue Proteins/genetics , RNA, Small Interfering/genetics , Animals , Brain/metabolism , Cells, Cultured , Disease Models, Animal , Embryonic Stem Cells/cytology , HEK293 Cells , Humans , Huntingtin Protein , Huntington Disease/genetics , In Vitro Techniques , Male , Mice , Mutant Proteins/genetics , Polymorphism, Single Nucleotide , RNA Isoforms/metabolism , RNA Stability , Rats , Rats, WistarABSTRACT
Good shift changeovers contribute to ensuring continuity and reliability in shift work. In situations where production is not maintained 24 h a day, changeovers with meetings (SCM) between the two work teams (written plus oral face-to-face handovers) alternate with changeovers without meetings (SCnM; written handovers only). An ergonomic work analysis on an aircraft assembly line showed that (1) incoming and outgoing operators met during the overlap time allotted by the company, and (2) the content of the exchanges was richer for SCMs than for SCnMs. SCMs enabled the operators to pass on and process more aspects of their work than SCnMs did. SCMs also allowed incoming operators to validate their predictions, and enabled both outgoing and incoming operators to update their mental models and work together on peripheral aspects of the technical process over a greater time span. The findings highlight the importance of allowing overlap time in shift work.
Subject(s)
Aircraft , Employment , Group Processes , Industry , Quality Control , France , HumansABSTRACT
Human pluripotent stem cells offer a limitless source of cells for regenerative medicine. Neural derivatives of human embryonic stem cells (hESCs) are currently being used for cell therapy in 3 clinical trials. However, hESCs are prone to genomic instability, which could limit their clinical utility. Here, we report that neural differentiation of hESCs systematically produced a neural stem cell population that could be propagated for more than 50 passages without entering senescence; this was true for all 6 hESC lines tested. The apparent spontaneous loss of evolution toward normal senescence of somatic cells was associated with a jumping translocation of chromosome 1q. This chromosomal defect has previously been associated with hematologic malignancies and pediatric brain tumors with poor clinical outcome. Neural stem cells carrying the 1q defect implanted into the brains of rats failed to integrate and expand, whereas normal cells engrafted. Our results call for additional quality controls to be implemented to ensure genomic integrity not only of undifferentiated pluripotent stem cells, but also of hESC derivatives that form cell therapy end products, particularly neural lines.
Subject(s)
Cell Differentiation/physiology , Chromosomes, Human, Pair 1/genetics , Embryonic Stem Cells/physiology , Genomic Instability , Animals , Cell Culture Techniques , Cell Line , Clinical Trials as Topic , Embryonic Stem Cells/cytology , Humans , Karyotyping , Neural Stem Cells/cytology , Neural Stem Cells/physiology , RatsABSTRACT
A multiprotein complex encompassing a transcription regulator, cardiac ankyrin repeat protein (CARP), and the calpain 3 protease was identified in the N2A elastic region of the giant sarcomeric protein titin. The present study aimed to investigate the function(s) of this complex in the skeletal muscle. We demonstrate that CARP subcellular localization is controlled by the activity of calpain 3: the higher the calpain 3, the more important the sarcomeric retention of CARP. This regulation would occur through cleavage of the N-terminal end of CARP by the protease. We show that, upon CARP over-expression, the transcription factor nuclear factor NF-κB p65 DNA-binding activity decreases. Taken as a whole, CARP and its regulator calpain 3 appear to occupy a central position in the important cell fate-governing NF-κB pathway. Interestingly, the expression of the atrophying protein MURF1, one of NF-κB main targets, remains unchanged in presence of CARP, suggesting that the pathway encompassing calpain 3/CARP/NF-κB does not play a role in muscle atrophy. With NF-κB also having anti-apoptotic effects, the inability of calpain 3 to lower CARP-driven inhibition of NF-κB could reduce muscle cell survival, hence partly accounting for the dystrophic pattern observed in limb girdle muscular dystrophy 2A, a pathology resulting from the protease deficiency.